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ABSTRACT
On 8 May 2004, the World Health Organization (WHO) and the United Nations Children’s Fund 
(UNICEF) recommended routine administration of zinc in the management of children, aged less 
than five years, with acute diarrhoea. In making the recommendation, WHO and UNICEF also sug-
gested careful monitoring for adverse events associated with routine administration of zinc, particu-
larly unusual or excess vomiting. The study assessed, in a phase IV trial, i.e. post-marketing surveillance 
of zinc, the occurrence of adverse events during the first hour after the administration of the first 
dose of zinc in children with acute or persistent diarrhoea. The study was conducted at the Dhaka 
Hospital of ICDDR,B and at an outpatient clinic operated by a local health NGO—Progoti Samaj Kal-
lyan Protisthan (PSKP), Dhaka, Bangladesh. Eligible children, aged 3-59 months, were treated with 
20 mg of zinc sulphate provided in a dispersible tablet formulation. The children were observed 
for 60 minutes following the initial treatment with zinc for adverse events, with particular atten-
tion given to vomiting or regurgitation. During the one-year observation period, 42,440 children 
(male 57% and female 43%) received zinc, and 20,246 (47.8%) of them were observed. Regurgitation 
and/or vomiting occurred in 4,392 (21.8%) of the children; 90.8% of these children had vomiting 
only once, 8.7% twice, and 0.5% more than twice. No children revisited the hospital for recurrent 
vomiting following their discharge. A significant proportion of infants and children may experience 
vomiting or regurgitation, usually once, following the administration of the first dose of zinc. This is 
a transient phenomenon that did not impact on continuation of treatment with zinc. 
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INTRODUCTION
Zinc, a micronutrient, is a component in many 
metallo-enzymes and poly-ribosomes involved 
in cellular function. It is essential for metabo-
lism, cellular growth, and immune function 
in humans (1). Zinc deficiency is widespread 
among children in developing countries where 
serious infectious diseases, such as diarrhoea, are 
common (2-3). The therapeutic effects of zinc in 
acute and persistent diarrhoea have been inves-
tigated in several studies and have consistently 
benefited young children in terms of reducing 
the severity and duration of episodes of diar-
rhoea and subsequent prevention of episodes 
(4-14). The World Health Organization (WHO) 
has estimated that 750,000 children die globally 
each year due to zinc deficiency (15), and it is 
estimated that over half of these deaths could 
be prevented through routine treatment with 
zinc as part of the management of childhood 
diarrhoea (16). Based upon all the evidence and 
in response to the recommendations of WHO/
United Nations Children’s Fund (UNICEF) (17), 
ICDDR,B decided to introduce zinc therapy in 
the routine management of children with acute 
or persistent diarrhoea at its hospital in Dhaka, 
Bangladesh. Khan AM et al. Routine zinc therapy for diarrhoea in children
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Side-effects, such as nausea and vomiting, fol-
lowing ingestion of zinc for the treatment of vari-
ous medical problems have been reported in 
adults and adolescents, but at higher doses, for 
example, in the management of non-responsive 
coeliac disease, sickle cell anaemia, and apthous 
ulcer (18). Acute zinc toxicity due to excess 
administration (225-450 mg of zinc) includes 
gastrointestinal symptoms, such as nausea, 
vomiting, epigastric pain, abdominal cramps, 
and bloody diarrhoea (18). Recent randomized 
clinical trials in adults and adolescents with 
acne, anorexia nervosa, macular degeneration, 
common cold, and tuberculosis, which used ele-
mental zinc in the dose range of 50-100 mg/
day, reported nausea and vomiting as side-ef-
fects (19-22). In two clinical trials with zinc 
among children, aged less than five years (un-
der-five children) with diarrhoea, vomiting was 
the only side-effect observed (10,23). In view of 
this information on zinc-related side-effects and 
the joint WHO/UNICEF recommendations to 
monitor for adverse events associated with zinc 
therapy, this study was undertaken to evaluate 
regurgitation and vomiting following the initial 
treatment with zinc. 
MATERIALS AND METHODS
Study design and approval
This was a phase IV safety study, i.e. post-mar-
keting surveillance of treatment with zinc for 
childhood diarrhoea to evaluate the occurrence 
of adverse events. The Research Review Com-
mittee and the Ethical Review Committee of 
ICDDR,B reviewed and approved the study.
Study time and site 
The  study  was  conducted  during  April  2004–
March 2005 at the Dhaka Hospital of ICDDR,B 
and an adjacent outpatient clinic operated by a 
local health NGO— Progoti Samaj Kallyan Protis-
than (PSKP)—located on the Centre’s premises. 
The Dhaka Hospital and the PSKP clinic provide 
treatment to around 110,000 patients with diar-
rhoea each year, most of whom are residents of 
urban and peri-urban Dhaka, the capital city of 
Bangladesh. The majority of the patients come 
from a poor socioeconomic background, living 
in city slums (Faruque ASG. Personal commu-
nication, 2006). Under-five children constitute 
about 50% of all patients, with malnutrition be-
ing very common among them. About 35-40% 
of all children attending the Dhaka Hospital are 
referred to and treated at the PSKP clinic, and 
about 55% are treated in the Short Stay Ward 
(SSW) of the Dhaka Hospital. The remaining 5-
10% are either admitted to an intermediate care 
ward  or  transferred  to  the  appropriate  health 
facility.   
Clinical practice guideline for zinc and study 
administration
Children of either sex, aged 3-59 months, attend-
ing the Dhaka Hospital of ICDDRB with uncom-
plicated diarrhoea, either admitted to the SSW or 
referred to the PSKP clinic, constituted the source 
population. Those with co-morbidities associated 
with excessive vomiting, e.g. whooping cough, 
pylorospasm, congenital pyloric stenosis, hiatus 
hernia, other obstructive defects of the gastrointes-
tinal tract, cow’s milk allergy, etc., were excluded 
from routine zinc therapy. Similarly, in addition 
to diarrhoea, children with any other systemic 
complications, e.g. pneumonia, meningitis, sep-
sis, paralytic ileus, severe malnutrition, hypogly-
caemia, serum electrolyte disorders, seizure, etc. 
that required admission to the longer-stay wards 
of the Dhaka Hospital, were also excluded. The de-
cision of administering zinc, outside this study, 
was left to the respective care-giving doctors.
Children were initially triaged and those with 
uncomplicated, mild diarrhoea having no sign 
of dehydration were referred to the PSKP clinic. 
Children with signs of dehydration, but with-
out serious co-morbidity, were admitted to the 
SSW of the Dhaka Hospital.
In the PSKP clinic, the usual stay of the chil-
dren was 1-2 hour(s), where they were given 
oral rehydration salts solution (ORS) and their 
usual foods. Here, children who fulfilled the 
study criteria were given their first dose of zinc 
when they were considered settled, i.e. not de-
hydrated, no vomiting in the last 30 minutes, 
and taking ORS as instructed. A trained research 
assistant observed each child for 60 minutes fol-
lowing ingestion of zinc and recorded regurgi-
tation and/or vomiting events. If an episode 
of vomiting or regurgitation was observed, the 
research assistant conducted a brief interview, 
with 13 questions, the parent gave verbal con-
sent to document illness-history. To compare 
the illness-history prior to giving zinc, for each 
child experiencing regurgitation and/or vomiting 
after the administration of zinc, another child 
was identified as a control (he/she did not have 
regurgitation and/or vomiting after giving zinc) Khan AM et al. Routine zinc therapy for diarrhoea in children
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by taking the next or the closest child registered. 
The admission characteristics, preparations, cri-
teria for administration of zinc, and observation 
period after giving zinc were similar in both the 
groups. Research assistants similarly conducted 
brief interview with the parent to document ill-
ness characteristics of control patients.         
In the SSW, patients were rehydrated using oral 
or intravenous fluids. Their usual stay in this 
ward was around 24 hours. Here also, children 
who met the study criteria received their first 
dose of zinc when they were considered settled, 
i.e. no vomiting in the past hour and hydrated. 
This usually required 6-8 hours. Children then 
were observed for 60 minutes after the adminis-
tration of zinc, and all regurgitation and/or vomit-
ing events were recorded. Here also, with verbal 
consent, the research assistants carried out the 
interview (13 questions) with the parent. In the 
similar manner, children for the control group 
to compare illness were selected, and their ill-
ness characteristics were recorded. 
While receiving zinc, whether in the SSW or 
at the PSKP clinic, doctors on duty at these sites 
assessed all children. In the SSW, the doctors as-
sessed all children at least two times in 24 hours, 
and the nurses provided 24-hour monitoring of 
the  children  for  development  of  any  unusual 
symptoms that might be related to zinc toxicity. 
Thus, all attending medical staff were advised to 
report any adverse event that could potentially 
be attributed to zinc treatment. 
Vomiting was defined as the forceful emptying 
of stomach contents and was recorded if it hap-
pened within 60 minutes following the admin-
istration of zinc. Regurgitation was defined 
as the unforceful return of any amount of the 
swallowed syrup or other stomach contents within 
five minutes of the administration of zinc. 
Treatment regimen
Every child in the study was prescribed 20 mg of 
zinc sulphate once daily for 10 days.
Zinc tablet formulation 
Nutriset Ltd. and Rodael Laboratory—both lo-
cated in France—produced the zinc premix, and 
a local pharmaceutical laboratory—Square Phar-
maceuticals—compressed this into dispersible 
tablets and packaged the tablets in aluminum 
blister packs (each tablet contains 20 mg of zinc 
sulphate). The tablets are vanilla-flavoured, and 
the metallic taste of zinc is masked using a non-
encapsulated, patented technology. The tablets 
quickly dissolve upon addition of a few drops of 
water, resulting in a syrup. 
Data analysis 
Data were entered and analyzed using the SPSS 
PC software (version 11.0). Data were re-entered 
to verify accuracy in a 10% sample of subjects. 
Errors in data entry occurred in less than 0.5% 
of the entries. The between-group differences 
were assessed by chi-square test, and a p value 
of <0.05 was considered significant. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were 
also calculated 
RESULTS
During the one-year study period, 42,440 chil-
dren aged less than five years received zinc, of 
which 20,246 (47.8%) were observed—12,233 in 
the PSKP clinic and 8,013 in the SSW. The rest 
could not be observed either because of lack of 
capacity at busy times (due to overflow of patients) 
to observe all children, direct discharge from 
the triage, and arrival of children before and after 
office hours and at night when no research assist-
ant was available.  Regurgitation and/or vomit-
ing occurred in 4,392 (21.8%) of the children 
(Fig. 1). Regurgitation alone occurred in 6.3%, 
vomiting alone occurred in 15.0%, and both 
occurred in 0.5% of the children. A history of 
vomiting during the past 24 hours prior to the 
administration of zinc was present in 85.8% of 
the children. Of the remaining children, 7.4% 
had no history of vomiting during their illness, 
and 6.8% had history of vomiting, but the last 
episode was before 24 hours of administration 
of zinc. Vomiting by children after ingestion of 
zinc occurred once in 90.8%, twice in 8.7%, and 
more than twice in 0.5% of them.
Comparison of illness (before giving zinc) of the 
two groups showed that significantly more chil-
dren had a history of vomiting in the past 24 
hours among those who regurgitated (53.0% vs 
47.0%, OR=2.0, p<0.001)) or vomited (51.2% vs 
48.8%, OR=2.2, p<0.001) after ingestion of zinc 
tablet (Figs. 2 and 3).  Similarly, the proportion 
of children who had a history of vomiting in the 
past three hours prior to giving zinc was signifi-
cantly higher among those with regurgitation 
(54.9% vs 45.1%, OR=2.2, p<0.001) or vomiting 
(65.3% vs 34.7%, OR=3.9, p<0.001) following Khan AM et al. Routine zinc therapy for diarrhoea in children
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the administration of zinc (Figs. 2 and 3). With 
the exception of vomiting and regurgitation, 
the attending medical staff did not observe any 
adverse events that could be attributed to the 
zinc treatment. No child was brought back to 
the hospital because of recurrent vomiting after 
discharge from the hospital.
DISCUSSION
To our knowledge, this is the first introduction 
of routine zinc therapy in a large hospital that 
treats childhood diarrhoea, irrespective of severity, 
and with or without complications. We used a 
dispersible tablet containing 20 mg of zinc sul-
phate. The tablets mask the metallic zinc taste. 
The advantages of the tablet formulation over 
the syrup formulation include its much lower 
cost (about half of that of a syrup formulation), 
accurate dosing, ease of storage, longer shelf-life, 
and ease of administration. This study focused 
exclusively on potential adverse events following 
the initial treatment with zinc in children aged 
less than five years, in particular vomiting and 
regurgitation. In this study, regurgitation and/
or vomiting occurred in 21.8% of the children 
following the administration of the first dose of 
zinc. This rate of vomiting and regurgitation is 
very similar to that observed among children 
receiving zinc in a randomized study conducted 
concurrently in the same setup by Larson et al. 
(23). Patient-selection criteria, study prepara-
tions, zinc tablet formulation, its dose, and ob-
servations before and after giving zinc were same 
in those children as ours, and they were rando-
mized to one of three groups: no treatment, 
placebo, or zinc sulphate 20 mg. The study by 
Larson et al. also showed that 58 (10.9%) of 533 
children who did not receive zinc (only ORS) 
had experienced regurgitation and/or vomit-
ing—regurgitation alone in 2.1% and vomiting 
alone in 8.8%. The age and sex distribution of 
those children were comparable with those of 
our study children. Comparison of the results 
of these two studies would indicate that the in-
cidence of regurgitation and vomiting occurred 
in significantly higher proportions of children 
who received zinc (2 times higher probability) 
than those who did not receive zinc (21.8% vs 
10.9%; OR=2.3, 95% CI 1.72-3.04; p<0.001).    
Vomiting following the administration of oral 
medications is frequently observed among chil-
dren  admitted  to  our  hospital.  This  back-
ground cause of vomiting and vomiting due 
to diarrhoeal illness cannot be separated from 
vomiting due to zinc tablet formulation in this 
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study. In this study, more than 90% of the chil-
dren experienced vomiting only once, and the 
chances were more for children who had a his-
tory of vomiting along with their diarrhoea. 
This is also consistent with the results of the 
study carried out by Larson et al. (23). Together, 
these findings support the early institution of 
zinc therapy after settling the child during epi-
sodes of diarrhoea. There is a risk for vomiting 
but it occurs only once in the large majority of 
cases and is unlikely to be of major clinical sig-
nificance, i.e. interruption of zinc therapy or in-
terference with maintenance of hydration using 
oral rehydration fluids. 
There are important limitations to this study 
affecting generalization and clinical interpreta-
tion of the study’s findings. The study popula-
tion included children who were brought to 
the ICDDR,B hospital, locally known as the 
‘Cholera Hospital’. These children are repre-
sentative of the more severe end of the illness 
spectrum. While less than one-half presented 
with signs of dehydration, over 90% had a his-
tory of vomiting during the illness. It appears 
that vomiting is a major factor affecting the deci-
sion to seek help at the Centre.  Only 7% of all 
subjects reported no history of vomiting during 
their diarrhoeal illness, and 86% reported hav-
ing vomited in the past 24 hours. The absolute 
increase in vomiting attributable to zinc will 
Fig. 2. Comparison of illness before administration of zinc
<24 hours <3 hours
Case: Children who regurgitated after zinc administration
Control: Children who did not regurgitate after zinc administration
 p<0.001 p<0.001
%
 
o
f
 
c
h
i
l
d
r
e
n
 
w
i
t
h
 
h
i
s
t
o
r
y
 
o
f
 
v
o
m
i
t
i
n
g
 
b
e
f
o
r
e
 
z
i
n
c
a
d
m
i
n
i
s
t
r
a
t
i
o
n
0
10
20
30
40
50
60
likely be significantly less among children treat-
ed at home. A second limitation in this study 
is the one-hour observation of children. For 
ethical reasons, it was concluded that children 
should not be denied zinc therapy, therefore the 
decision to restrict the period of time for admin-
istration of zinc was withheld. This study does 
not address continued vomiting or vomiting 
following subsequent doses. A third limitation 
is the fact that this study used tablets prepared 
from a single premix shipped from France. It is 
possible that there are properties unique to this 
batch that have caused the vomiting.
Future studies monitoring side-effects of zinc 
need to consider alternative treatment protocols. 
For example, would an initial dose of 10 mg giv-
en twice during the first day lessen the likeli-
hood of vomiting or regurgitation? Longer-term 
follow-up is indicated addressing such questions 
as whether or not vomiting continues to occur 
with subsequent doses and does it continue once 
the illness subsides. There is also a need to con-
tinue to work towards improving zinc tablet for-
mulations that have a minimal risk for side-ef-
fects. This could include alternative zinc tablet 
preparations, such as zinc acetate. The masking 
of the zinc taste in the tablets is quite effective, 
but involves a patented technology that does 
not encapsulate to zinc. This non-encapsulation 
technique significantly reduces the cost of the Khan AM et al. Routine zinc therapy for diarrhoea in children
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formulation,  but  results  in  direct  exposure  of 
the oesophageal mucosa to zinc that can lead to 
local irritation and vomiting as a consequence. 
Encapsulated zinc formulations would be bet-
ter tolerated, however lower-cost encapsulation 
techniques need to be developed. Finally, and 
most importantly, it needs to be confirmed that 
any additional risk for vomiting or regurgitation 
does not result in unacceptable levels of clini-
cally significant adverse outcomes.  
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